DWM
REGN icon

Destination Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Destination Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12
Closed -$5K – 672
2018
Q3 		$5K Buy
+12
New +$4.57K ﹤0.01% 518
2015
Q3 		– Sell
-500
Closed -$255K – 202
2015
Q2 		$255K Buy
+500
New +$244K 0.02% 213

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Destination Wealth Management's REGN Position: Q4 2018 in Review

Destination Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 12 shares — an estimated $5K sold.

Destination Wealth Management first reported a position in REGN in Q2 2015 and held it in 2 quarters. The position peaked at $255K in Q2 2015. 671 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

  • Destination Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Destination Wealth Management sold 12 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $5K.
  • Destination Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Destination Wealth Management's Regeneron Pharmaceuticals position peaked at $255K in Q2 2015.
  • 671 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Destination Wealth Management's 13F filing for Q4 2018, filed 5 Feb 2019.